VBIO VALION BIO INC revenue, earnings and financials

For the quarter ended June 30, 2026, VALION BIO INC reported revenue of n/a, net income of −$7.10M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.

VBIO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$7.90M, net income −$8.88M (margin n/a), EPS n/a
• Fiscal year ended Dec 2024: revenue $780K, gross profit $2.00K, operating income −$4.48M, net income −$5.66M (margin -725.0%), EPS −$19.68
• Fiscal year ended Dec 2023: revenue $1.18M, gross profit $287K, operating income −$8.25M, net income −$8.24M (margin -701.0%), EPS −$176.80
• Fiscal year ended Dec 2022: revenue $1.84M, gross profit $299K, operating income −$10.1M, net income −$10.1M (margin -548.7%), EPS −$104.32
• Fiscal year ended Dec 2021: revenue $1.26M, gross profit −$38.0K, operating income −$5.63M, net income −$8.49M (margin -675.7%), EPS −$2.43

VBIO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$7.10M, EPS n/a
• Quarter ended Mar 31, 2026: revenue n/a, net income −$6.20M, EPS n/a
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.85M, EPS n/a
• Quarter ended Sep 30, 2025: revenue $146K (up 15.9% year over year), net income −$2.60M, EPS n/a
• Quarter ended Jun 30, 2025: revenue $86.0K (down 38.6% year over year), net income −$1.93M, EPS −$2.19
• Quarter ended Mar 31, 2025: revenue $70.0K (down 79.0% year over year), net income −$1.50M, EPS −$2.52
• Quarter ended Dec 31, 2024 (from the annual report): revenue $180K (down 49.6% year over year), net income −$1.48M, EPS $3.07
• Quarter ended Sep 30, 2024: revenue $126K (down 55.3% year over year), net income −$1.43M, EPS −$0.23
• Quarter ended Jun 30, 2024: revenue $140K (down 13.0% year over year), net income −$1.27M, EPS −$5.37
• Quarter ended Mar 31, 2024: revenue $334K (down 11.2% year over year), net income −$1.48M, EPS −$17.15
• Quarter ended Dec 31, 2023 (from the annual report): revenue $357K (down 12.3% year over year), net income −$2.24M, EPS −$157.64
• Quarter ended Sep 30, 2023: revenue $282K (down 40.9% year over year), net income −$1.76M, EPS −$1.48
• Quarter ended Jun 30, 2023: revenue $161K (down 69.5% year over year), net income −$2.13M, EPS −$7.16
• Quarter ended Mar 31, 2023: revenue $376K (down 12.1% year over year), net income −$2.12M, EPS −$10.52
• Quarter ended Dec 31, 2022 (from the annual report): revenue $407K (up 4.6% year over year), net income −$2.25M, EPS −$76.77
• Quarter ended Sep 30, 2022: revenue $477K (up 72.2% year over year), net income −$2.58M, EPS −$27.00
• Quarter ended Jun 30, 2022: revenue $528K (up 97.0% year over year), net income −$3.02M, EPS −$0.32
• Quarter ended Mar 31, 2022: revenue $428K (up 32.5% year over year), net income −$2.24M, EPS −$0.23
• Quarter ended Dec 31, 2021 (from the annual report): revenue $389K, net income −$3.72M, EPS −$0.49
• Quarter ended Sep 30, 2021: revenue $277K, net income −$2.32M, EPS −$0.90

VBIO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$7.00M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$5.73M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$8.51M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$8.92M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$5.61M, share buybacks n/a

VBIO balance sheet

• Jun 30, 2026: cash $2.11M, total assets $32.5M, total liabilities $20.6M, shareholders' equity $4.25M
• Mar 31, 2026: cash $7.22M, total assets $38.2M, total liabilities $19.7M, shareholders' equity $11.1M
• Dec 31, 2025: cash $12.6M, total assets $31.6M, total liabilities $7.44M, shareholders' equity $16.8M
• Sep 30, 2025: cash $3.45M, total assets $6.23M, total liabilities $638K, shareholders' equity $3.41M
• Jun 30, 2025: cash $1.18M, total assets $4.51M, total liabilities $821K, shareholders' equity $3.69M
• Mar 31, 2025: cash $669K, total assets $3.78M, total liabilities $741K, shareholders' equity $3.04M
• Dec 31, 2024: cash $2.00M, total assets $2.81M, total liabilities $272K, shareholders' equity $2.54M
• Sep 30, 2024: cash $2.19M, total assets $3.39M, total liabilities $560K, shareholders' equity $2.83M

Is VBIO profitable?

No. VALION BIO INC lost $18.8M over the last four quarters.

VBIO ownership and insider trades · All stocks